(Q37892114)

English

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

scientific article published on 12 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

based on heuristic

inferred from title

author name string

Alan S Bass

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Hugo M Vargas

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Jean-Pierre Valentin

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lewis B Kinter

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Tim Hammond

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Rob Wallis

6

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Peter K S Siegl

7

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Keiji Yamamoto

8

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

publication date

12 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Journal of Pharmacological and Toxicological Methods

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

7-15

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Origins, practices and future of safety pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Exploratory drug safety: a discovery strategy to reduce attrition in development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Paediatric and geriatric drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

High throughput functional screening of an ion channel library for drug safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Proof of concept: a PhRMA position paper with recommendations for best practice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Safety Pharmacology Society: 5th annual meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Safety Pharmacology Society: 7th annual meeting 19 - 20 September 2007, Edinburgh, UK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Safety Pharmacology Society: 8th annual meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Safety Pharmacology Society: 9th Annual Meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

10th annual meeting of the Safety Pharmacology Society: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

What is the future role of pharmacologists in the pharmaceutical industry?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Use and application of stem cells in toxicology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Pharmacological validation of a semi-automated in vitro hippocampal brain slice assay for assessment of seizure liability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

In silico prediction of drug safety: despite progress there is abundant room for improvement

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Pharmacological validation of a telemetric model for the measurement of bronchoconstriction in conscious rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

The psychoactive effects of antidepressants and their association with suicidality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Nonclinical proarrhythmia models: predicting Torsades de Pointes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Healthy volunteer dies in US physiology study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Sir James Black (1924-2010).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Cardiotoxicity associated with targeting kinase pathways in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Current approaches and issues in non-clinical evaluation of abuse and dependence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Lessons from 60 years of pharmaceutical innovation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

A call for sharing: adapting pharmaceutical research to new realities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Comprehensive non-clinical respiratory evaluation of promising new drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Modeling the heart--from genes to cells to the whole organ

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Modeling the heart

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Principles of safety pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Validation of the use of zebrafish larvae in visual safety assessment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Can pharmacogenetics help rescue drugs withdrawn from the market?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

A model for human ventricular tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Reducing QT liability and proarrhythmic risk in drug discovery and development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Safety and secondary pharmacology: successes, threats, challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

A framework to assess the translation of safety pharmacology data to humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Challenges facing pharmacology--the in vivo situation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Validation of a larval zebrafish locomotor assay for assessing the seizure liability of early-stage development drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Predictive value of animal studies in toxicology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

In vivo drug discovery in the zebrafish

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.006

7 January 2021

Identifiers

10.1016/J.VASCN.2011.05.006

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37892114&oldid=1760424159"